Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus plantarum Y44
- Development stage
- Preclinical
- Lead developer
- Dalian Polytechnic University
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus plantarum Y44 is a specific probiotic strain of the species *Lactobacillus plantarum* (recently reclassified as *Lactiplantibacillus plantarum*). It has been investigated for its antioxidant activity and its ability to survive gastric and intestinal transit. In preclinical studies involving obese mice fed a high-fat diet, L. plantarum Y44 demonstrated the potential to ameliorate intestinal inflammation and lipid metabolism disorders. Its mechanism of action involves the modulation of gut microbiota, leading to an increase in short-chain fatty acid (SCFA) production and a reduction in the Firmicutes/Bacteroidetes ratio. Furthermore, it regulates lipid metabolism by inhibiting the expression of fatty acid synthase (FAS) and acetyl-CoA carboxylase (ACC) in the liver, strengthens the intestinal barrier by up-regulating tight junction proteins such as claudin-1 and occludin, and reduces systemic inflammation by down-regulating the p38 MAPK pathway and lowering levels of pro-inflammatory cytokines like IL-8 and TNF-α.
- Other names
- L. plantarum Y44Lactiplantibacillus plantarum Y44
02
Targets
IL8 (C-X-C Motif Chemokine Ligand 8)TNFA (Tumor necrosis factor alpha (soluble))CLDN1 (Tight junction protein claudin-1)ACC (Acetyl-CoA Carboxylase 1)FASN (Fatty acid synthase)RK (Ribokinase)OCLN (Occludin)
Beyond the preview
Go deeper on Lactobacillus plantarum Y44.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus plantarum Y44.